Skip to main content
SpringerLink
Log in

Meta-analysis of Dropout Rates in Placebo-Controlled Randomized Clinical Trials of Atypical Antipsychotics Assessed by PANSS

  • Systematic Review
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and Objectives

Subject dropout rates in placebo-controlled randomized clinical trials (RCTs) of antipsychotics are high. The missing values due to dropout represent a potential source of bias in clinical trials. We aimed to identify the potential factors affecting subject dropout in atypical antipsychotics RCTs by conducting a meta-analysis.

Methods

Placebo-controlled RCTs for atypical antipsychotics using positive and negative syndrome scale (PANSS) as a psychiatric assessment scale were selected by database search. The potential factors affecting subject dropout, such as publication year, study design, and operational factors, were analyzed by meta-regression.

Results

Forty-seven placebo controlled RCTs of atypical antipsychotics of which results were published between 1993 and 2018 were identified through the database search. In the multivariate meta-regression analysis, earlier publication year, older age of subjects, and longer study duration were significantly associated with high subject dropout rates in placebo-controlled clinical trials of atypical antipsychotics.

Conclusion

Subject dropout rates in clinical trials of atypical antipsychotics published between 1993 and 2018 year decreased over time. Study duration should be taken into consideration when designing future studies, where short study periods yet appropriate for evaluating the efficacy of new atypical antipsychotics are preferable. Additionally, previous medications and the degree of subject satisfaction with antipsychotics might affect subject dropout rate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Lewis JA, Jonsson B, Kreutz G, Sampaio C, van Zwieten-Boot B. Placebo-controlled trials and the Declaration of Helsinki. Lancet. 2002;359(9314):1337–40. https://doi.org/10.1016/s0140-6736(02)08277-6.

    Article  PubMed  Google Scholar 

  2. Miller FG. Placebo-controlled trials in psychiatric research: an ethical perspective. Biol Psychiatry. 2000;47(8):707–16.

    Article  CAS  Google Scholar 

  3. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trial E9. 1998. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf. Accessed 27 Jun 2019.

  4. Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62(12):1305–12. https://doi.org/10.1001/archpsyc.62.12.1305.

    Article  PubMed  Google Scholar 

  5. Wahlbeck K, Tuunainen A, Ahokas A. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology. 2001;155(3):230–3. https://doi.org/10.1007/s0021301007.

    Article  PubMed  CAS  Google Scholar 

  6. Rabinowitz J, Levine SZ, Barkai O, Davidov O. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull. 2009;35(4):775–88. https://doi.org/10.1093/schbul/sbn005.

    Article  PubMed  Google Scholar 

  7. Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity. J Nerv Ment Dis. 1992;180(11):723–8.

    Article  CAS  Google Scholar 

  8. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76. https://doi.org/10.1093/schbul/13.2.261.

    Article  PubMed  CAS  Google Scholar 

  9. Overall JE. Commentary on the BPRS by John Overall in 1978 at Citation Classics. 1979. http://www.garfield.library.upenn.edu/classics1979/A1979HZ19700001.pdf. Accessed Apr 2017.

  10. Matsusaki A, Kaneko M, Narukawa M. Meta-analysis of placebo response in randomized clinical trials of antipsychotic drugs using PANSS focusing on different approaches to the handling of missing data. Clin Drug Investig. 2018;38(8):751–61. https://doi.org/10.1007/s40261-018-0661-1.

    Article  PubMed  Google Scholar 

  11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.

    Article  CAS  Google Scholar 

  12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009. https://doi.org/10.1136/bmj.b2700.

    Article  PubMed  PubMed Central  Google Scholar 

  13. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2017-04-21. 2017. https://www.R-project.org/. Accessed Apr 2017.

  14. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13(1):25–40.

    Article  CAS  Google Scholar 

  15. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825–35. https://doi.org/10.1176/ajp.151.6.825.

    Article  PubMed  CAS  Google Scholar 

  16. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996;124(1–2):159–67.

    Article  CAS  Google Scholar 

  17. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl). 1996;124(1–2):168–75.

    Article  Google Scholar 

  18. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20(5):491–505. https://doi.org/10.1016/s0893-133x(98)00090-6.

    Article  PubMed  CAS  Google Scholar 

  19. Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Riviïre M-E, Papillon-Downey C. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J Psychiatry. 1999;156(3):419–25. https://doi.org/10.1176/ajp.156.3.419.

    Article  PubMed  CAS  Google Scholar 

  20. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63(9):763–71.

    Article  CAS  Google Scholar 

  21. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64(9):1048–56.

    Article  CAS  Google Scholar 

  22. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60(7):681–90. https://doi.org/10.1001/archpsyc.60.7.681.

    Article  PubMed  CAS  Google Scholar 

  23. Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006;85(1–3):254–65. https://doi.org/10.1016/j.schres.2006.03.027.

    Article  PubMed  Google Scholar 

  24. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1–3):117–30. https://doi.org/10.1016/j.schres.2007.03.003.

    Article  PubMed  Google Scholar 

  25. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):832–42.

    Article  CAS  Google Scholar 

  26. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1–3):147–61. https://doi.org/10.1016/j.schres.2006.09.012.

    Article  PubMed  CAS  Google Scholar 

  27. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363–70. https://doi.org/10.1016/j.biopsych.2007.01.017.

    Article  PubMed  CAS  Google Scholar 

  28. McEvoy JP, Daniel DG, Carson WH Jr, McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res. 2007;41(11):895–905. https://doi.org/10.1016/j.jpsychires.2007.05.002.

    Article  PubMed  Google Scholar 

  29. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492–500.

    Article  CAS  Google Scholar 

  30. Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl). 2008;200(3):317–31. https://doi.org/10.1007/s00213-008-1207-7.

    Article  CAS  Google Scholar 

  31. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S20–8. https://doi.org/10.1097/jcp.0b013e318169d4ce.

    Article  PubMed  CAS  Google Scholar 

  32. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S4–11. https://doi.org/10.1097/jcp.0b013e3181692787.

    Article  PubMed  CAS  Google Scholar 

  33. Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry. 2009;166(6):691–701. https://doi.org/10.1176/appi.ajp.2009.08040613.

    Article  PubMed  Google Scholar 

  34. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829–36. https://doi.org/10.4088/jcp.08m04905.

    Article  PubMed  CAS  Google Scholar 

  35. Cutler AJ, Tran-Johnson T, Kalali A, Astrom M, Brecher M, Meulien D. A failed 6-week, randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned. Psychopharmacol Bull. 2010;43(4):37–69.

    PubMed  Google Scholar 

  36. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106–15. https://doi.org/10.1097/jcp.0b013e3181d35d6b.

    Article  PubMed  CAS  Google Scholar 

  37. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31(3):349–55. https://doi.org/10.1097/jcp.0b013e318218dcd5.

    Article  PubMed  CAS  Google Scholar 

  38. Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957–67. https://doi.org/10.1176/appi.ajp.2011.10060907.

    Article  PubMed  Google Scholar 

  39. Redden L, Rendenbach-Mueller B, Abi-Saab WM, Katz DA, Goenjian A, Robieson WZ, et al. A double-blind, randomized, placebo-controlled study of the dopamine D(3) receptor antagonist ABT-925 in patients with acute schizophrenia. J Clin Psychopharmacol. 2011;31(2):221–5. https://doi.org/10.1097/jcp.0b013e31820e4818.

    Article  PubMed  CAS  Google Scholar 

  40. Schmidt ME, Kent JM, Daly E, Janssens L, Van Osselaer N, Husken G, et al. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D(2) receptor antagonist in the treatment of acute exacerbation of schizophrenia. Eur Neuropsychopharmacol. 2012;22(10):721–33. https://doi.org/10.1016/j.euroneuro.2012.02.007.

    Article  PubMed  CAS  Google Scholar 

  41. Egan MF, Zhao X, Smith A, Troyer MD, Uebele VN, Pidkorytov V, et al. Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia. Hum Psychopharmacol. 2013;28(2):124–33. https://doi.org/10.1002/hup.2289.

    Article  PubMed  CAS  Google Scholar 

  42. Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145(1–3):101–9. https://doi.org/10.1016/j.schres.2013.01.009.

    Article  PubMed  Google Scholar 

  43. Nasrallah HA, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670–7. https://doi.org/10.1016/j.jpsychires.2013.01.020.

    Article  PubMed  Google Scholar 

  44. Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225(3):519–30. https://doi.org/10.1007/s00213-012-2838-2.

    Article  CAS  Google Scholar 

  45. Bugarski-Kirola D, Wang A, Abi-Saab D, Blattler T. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia—results from the CandleLyte study. Eur Neuropsychopharmacol. 2014;24(7):1024–36. https://doi.org/10.1016/j.euroneuro.2014.03.007.

    Article  PubMed  CAS  Google Scholar 

  46. Downing AM, Kinon BJ, Millen BA, Zhang L, Liu L, Morozova MA, et al. A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry. 2014;14:351. https://doi.org/10.1186/s12888-014-0351-3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2–3):450–7. https://doi.org/10.1016/j.schres.2013.11.041.

    Article  PubMed  Google Scholar 

  48. Shen JH, Zhao Y, Rosenzweig-Lipson S, Popp D, Williams JB, Giller E, et al. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. J Psychiatr Res. 2014;53:14–22. https://doi.org/10.1016/j.jpsychires.2014.02.012.

    Article  PubMed  Google Scholar 

  49. Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870–80. https://doi.org/10.1176/appi.ajp.2015.14101275.

    Article  PubMed  Google Scholar 

  50. Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574–82. https://doi.org/10.4088/jcp.15m09997.

    Article  PubMed  Google Scholar 

  51. Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1–3):127–35. https://doi.org/10.1016/j.schres.2015.01.038.

    Article  PubMed  Google Scholar 

  52. Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367–73. https://doi.org/10.1097/jcp.0000000000000346.

    Article  PubMed  CAS  Google Scholar 

  53. Potkin SG, Kimura T, Guarino J. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther Adv Psychopharmacol. 2015;5(6):322–31. https://doi.org/10.1177/2045125315606027.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology (Berl). 2016;233(14):2663–74. https://doi.org/10.1007/s00213-016-4295-9.

    Article  CAS  Google Scholar 

  55. Landbloom R, Mackle M, Wu X, Kelly L, Snow-Adami L, McIntyre RS, et al. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr. 2016. https://doi.org/10.1017/s1092852916000377.

    Article  PubMed  Google Scholar 

  56. Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016;79(12):952–61. https://doi.org/10.1016/j.biopsych.2015.08.026.

    Article  PubMed  CAS  Google Scholar 

  57. Cantillon M, Prakash A, Alexander A, Ings R, Sweitzer D, Bhat L. Dopamine serotonin stabilizer RP5063: a randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder. Schizophr Res. 2017;189:126–33. https://doi.org/10.1016/j.schres.2017.01.043.

    Article  PubMed  Google Scholar 

  58. Ishigooka J, Iwashita S, Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2018;72(9):692–700. https://doi.org/10.1111/pcn.12682.

    Article  PubMed  CAS  Google Scholar 

  59. Gharabawi GM, Greenspan A, Rupnow MF, Kosik-Gonzalez C, Bossie CA, Zhu Y, et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry. 2006;6:45. https://doi.org/10.1186/1471-244x-6-45.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Schoemaker JH, Vingerhoets A, Emsley RA. Factors associated with poor satisfaction with treatment and trial discontinuation in chronic schizophrenia. CNS Spectr. 2018. https://doi.org/10.1017/s109285291700044x.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan

    Akiko Matsusaki, Masayuki Kaneko & Mamoru Narukawa

Authors
  1. Akiko Matsusaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masayuki Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mamoru Narukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akiko Matsusaki.

Ethics declarations

Conflict of interest

All authors have no conflicts of interest that are directly relevant to this research. Akiko Matsusaki is an employee of Chugai Pharmaceutical Co., Ltd.

Funding

The preparation of this manuscript was not supported by any external funding.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 283 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matsusaki, A., Kaneko, M. & Narukawa, M. Meta-analysis of Dropout Rates in Placebo-Controlled Randomized Clinical Trials of Atypical Antipsychotics Assessed by PANSS. Clin Drug Investig 39, 917–926 (2019). https://doi.org/10.1007/s40261-019-00813-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-019-00813-5

Search

Navigation